Pacira BioSciences Inc - Company Profile
Powered by 
All the data and insights you need on Pacira BioSciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Pacira BioSciences Inc Strategy Report
- Understand Pacira BioSciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Pacira BioSciences Inc (Pacira), formerly Pacira Pharmaceuticals Inc, provides non-opioid pain management and regenerative health solutions. The company develops drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic administered at the time of surgery to control pain and eliminate the use of opioids for acute postsurgical pain. Its other products include iovera, a non-opioid treatment intended to block pain, and relieve pain and symptoms related to osteoarthritis of the knee; among others. Its products are essentially used by hospitals, doctors and ambulatory surgery centers. It also sells products through co-promotion agreements and supply agreements with other pharmaceutical companies. The company has operations in the US and the UK. Pacira is headquartered in Tampa, Florida, the US.
Headquarters
United States of America
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, Florida, 33609
Website
www.pacira.com
Telephone
1 813 5536680
No of Employees
711
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PCRX (NASD)
Revenue (2022)
$675.0M
1.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
163.7%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
160.3%
(2022 vs 2021)
* As of and is in US$
Pacira BioSciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Exparel - Surgical Infiltration and Interscalene Brachial Plexus Nerve Block | Pacira |
| Iovera System - Total Knee Arthroplasty and Blocking of Pain | EXPAREL |
| Zilretta - Management of OA knee pain | DepoCyt |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In November, the company secured approval from the U.S. Food and Drug Administration for its supplemental new drug application (sNDA) to expand the EXPAREL (bupivacaine liposome injectable suspension) label. |
| 2023 | Contracts/Agreements | In February, the company and the Ladies Professional Golf Association entered into a partnership to make Pacira’s medical device ioveraº the Official Non-Opioid Pain Management Partner of the LPGA. |
| 2022 | Contracts/Agreements | In August, the company and Pacira BioSciences teamed up to educate athletes and communities about non-opioid options to manage pain. |
Competitor Comparison
| Key Parameters | Pacira BioSciences Inc | Napp Pharmaceuticals Ltd | DURECT Corp | Talphera Inc | Akorn Operating Company LLC |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | United States of America | United States of America | United States of America |
| City | Tampa | Cambridge | Cupertino | San Mateo | Gurnee |
| State/Province | Florida | England | California | California | Illinois |
| No. of Employees | 711 | 194 | 58 | 15 | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul J. Hastings | Chairman | Executive Board | 2024 | - |
| Frank D. Lee | Director; Chief Executive Officer | Executive Board | 2024 | - |
| Charles A. Reinhart III | Chief Financial Officer | Senior Management | 2016 | 62 |
| Daryl Gaugler | Chief Operating Officer | Senior Management | 2022 | 61 |
| Ronald Ellis | Chief Strategy Officer | Senior Management | 2022 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward